Vamorolone
Orphan DrugFDA Approved
Description
Vamorolone is an oral dissociative corticosteroid approved for Duchenne muscular dystrophy. It was developed to preserve anti-inflammatory activity while potentially reducing some steroid-related toxicities, making it a differentiated specialty option in an orphan neuromuscular disease. Global access has expanded through multiple regulatory pathways outside the United States as well.
Indications & Therapeutic Use
Duchenne muscular dystrophy
Linked Diseases:
Duchenne Muscular Dystrophy
G71.01D020388
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Vamorolone
| Generic Name | vamorolone |
| Brands | 1 brand available |
| Active Ingredient | vamorolone |
| Drug Class | Duchenne muscular dystrophy |
| Manufacturer | Santhera Pharmaceuticals |
| Dosage Forms | Oral suspension |
| Medical Code | H02AB |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02760264 |
| Countries | 2 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes